# US 2025/0375409 A1 · Treatment of REM Behavior Disorder

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0375409 A1
- Document ID: US20250375409A1
- Status: Published application
- Kind: A1
- Application number: 19/234,687
- Filed: 2025-06-11
- Published: 2025-12-11
- Earliest claimed: 2024-06-11
- Assignees: Vanda Pharmaceuticals Inc.
- Applicants: Vanda Pharmaceuticals Inc.
- Inventors: Mihael Polymeropoulos
- Web page: https://patentgrep.com/patent/US20250375409A1

## CPC

- A61K 31/343: condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Embodiments of the invention relate generally to the treatment of sleep-related disorders. One aspect of the invention includes a method of treating a patient suffering from rapid eye movement (REM) behavior disorder (RBD) comprising: administering to the patient an effective dose of tasimelteon before bedtime.

## Claims

### Claim 1

A method of treating a patient suffering from rapid eye movement (REM) behavior disorder (RBD) comprising:
administering to the patient an effective dose of tasimelteon before bedtime.

### Claim 2 (depends on 1)

The method of claim 1, wherein the effective dose of tasimelteon is a dose effective to alleviate at least one symptom of RBD.

### Claim 3 (depends on 1)

The method of claim 1, wherein the effective dose of tasimelteon is 20 mg/day.

### Claim 4 (depends on 1)

The method of claim 1, wherein the patient suffers from a neurodegenerative disorder.

### Claim 5 (depends on 4)

The method of claim 4, wherein the neurodegenerative disorder is Parkinson's disease.

### Claim 6 (depends on 1)

The method of claim 1, wherein the patient is one for whom treatment with a benzodiazepine is contraindicated.

### Claim 7 (depends on 1)

The method of claim 1, wherein the patient is being treated with a selective serotonin reuptake inhibitor.

### Claim 8

In a method of administering tasimelteon to a patient, the improvement comprising:
selecting as said patient an individual suffering from rapid eye movement (REM) behavior disorder (RBD).

### Claim 9 (depends on 8)

The improvement of claim 8, wherein administering tasimelteon to the patient includes administering an effective dose of tasimelteon before bedtime.

### Claim 10 (depends on 9)

The improvement of claim 9, wherein the effective dose is 20 mg/day.

### Claim 11 (depends on 8)

The improvement of claim 8, wherein the patient suffers from a neurodegenerative disorder.

### Claim 12 (depends on 11)

The improvement of claim 11, wherein the neurodegenerative disorder is Parkinson's disease.

### Claim 13 (depends on 8)

The improvement of claim 8, wherein the patient is one for whom treatment with a benzodiazepine is contraindicated.

### Claim 14 (depends on 8)

The improvement of claim 8, wherein the patient is being treated with a selective serotonin reuptake inhibitor.

### Claim 15

A method of treating a patient suffering from rapid eye movement (REM) behavior disorder (RBD) in whom treatment with a benzodiazepine was ineffective, the method comprising:
administering to the patient an effective dose of tasimelteon before bedtime.

### Claim 16 (depends on 15)

The method of claim 15, wherein the effective dose of tasimelteon is a dose effective to alleviate at least one symptom of RBD.

### Claim 17 (depends on 15)

The method of claim 15, wherein the effective dose of tasimelteon is 20 mg/day.

### Claim 18 (depends on 15)

The method of claim 15, wherein the patient suffers from a neurodegenerative disorder.

### Claim 19 (depends on 18)

The method of claim 18, wherein the neurodegenerative disorder is Parkinson's disease.
